In Taiwan, epidermal growth factor receptor (EGFR) mutations are the most common disease-associated mutations in lung cancer with an incidence rate around 55% [2, 3], and several EGFR tyrosine kinase inhibitors (EGFR-TKIs) are used as first-line therapy [3–7]. This evidence concerns the gene EGFR and lung carcinoma.